Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2023-09-28 00:00:00 ET · period of report 2023-09-26 · accession 0000905148-23-001029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-28 | 2023-09-26 | ACRV | Miller Mary | CLO | A - Grant | $0.00 | +3,858 | 44.3K | +10% | $0 |
| D | 2023-09-28 | 2023-09-26 | ACRV | Miller Mary | CLO | A - Grant | $0.00 | +11.6K | 11.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-26 | A | A | 3,858 | $0.00 | 44,287 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-09-26 | A | A | 11,576 | $0.00 | 11,576 | D | $8.95 · — to 2033-09-25 | 11,576 Common Stock | (F2) Twenty-five percent (25%) of the shares subject to the option shall vest on October 1, 2024, and the remaining shares subject to the option shall vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |